Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (Diluted Average) (2018 - 2025)

United Therapeutics' Shares Outstanding (Diluted Average) history spans 11 years, with the latest figure at $47.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 1.24% year-over-year to $47.9 million; the TTM value through Dec 2025 reached $47.9 million, down 1.24%, while the annual FY2025 figure was $47.9 million, 1.24% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $47.9 million at United Therapeutics, roughly flat from $48.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $49.7 million in Q4 2023 and bottomed at $46.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $48.2 million (2022), against an average of $48.3 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) rose 7.21% in 2021 before it dropped 4.23% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $47.3 million in 2021, then increased by 2.54% to $48.5 million in 2022, then grew by 2.47% to $49.7 million in 2023, then dropped by 2.41% to $48.5 million in 2024, then dropped by 1.24% to $47.9 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Shares Outstanding (Diluted Average) are $47.9 million (Q4 2025), $48.1 million (Q3 2025), and $48.3 million (Q2 2025).